The constraint isn't the obstacle. It's the terrain.
Medical and legal validation of every asset, by market and by brand, built into production instead of bolted on at the end.
Why this rarely works
In most projects compliance comes last. The asset is designed, approved internally, and only then sent for review. It comes back with changes that force the artwork to be redone, and the calendar slips by weeks.
The problem isn't that review is slow. It's that review is treated as a downstream formality rather than a design constraint. A claim you cannot support isn't a legal problem — it's a concept problem, and it can be caught before anything is drawn.
What's included
Medical validation of content
Review of claims, terminology and references against the product's approved labeling. Anything that can't be sourced gets flagged before it reaches design.
Regulatory review by market
The same material is rarely approved identically in two markets. It gets adapted to local regulation — ANMAT in Argentina, ISP in Chile, and the equivalent authority wherever the brand operates.
MLR workflow operated, not just supported
Preparing the asset for the client's medical-legal-regulatory review cycle, including loading it into their platform where applicable, and following it through to approval.
Version-level traceability
What changed, who asked for it, against which reference, on what date. That's what lets you answer an audit months later without reconstructing anything from memory.
Why us
We run materials for pharmaceutical companies across several markets at once, under different regulators and calendars that don't line up. That forces validation to be part of the pipeline rather than a separate stage. Ethics isn't a selling point here: it's the condition for the material to ship at all.
Questions we get
Do you replace the company's medical or legal department?
No, and nobody should. Final approval always belongs to the client. What we do is make sure the asset arrives at that review already prepared — claims sourced, legal copy correct — so the cycle resolves in one pass instead of four.
Do you work on both patient-facing and HCP-facing materials?
Both, and they're treated differently from the start. What you can say to a healthcare professional is not what you can say to a patient, and that difference shapes the concept, not just the copy.
What about pharmacovigilance on channels with comments?
It's a real obligation and it's designed into the channel from the start: any potential adverse event or product complaint is routed into the company's own process within whatever window their procedure requires. It isn't something you solve after opening the account.
The other services
strategic consulting
Brand, audiences, channels and competitors, analysed inside the real regulatory frame of the product and the market it will run in.
See the service → 03medical and creative content
Educational and promotional content for professionals and patients, produced with the evidence up front and the craft intact.
See the service → 04omnichannel and engagement
Communication journeys for professionals and patients, coordinated across channels and measured end to end.
See the service → 05paid media and performance
Search, social and programmatic inside each platform's health policies, with no sensitive data ever entering a pixel.
See the service →